<DOC>
	<DOCNO>NCT00389155</DOCNO>
	<brief_summary>The purpose study test investigational drug , vinflunine ( BMS-710485 ) , combination gemcitabine patient Transitional Cell Carcinoma treat cisplatin . This study help determine whether vinflunine combination gemcitabine extend time period growth tumor gemcitabine alone .</brief_summary>
	<brief_title>First-Line Treatment Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine Patients Ineligible Receive Cisplatin-Based Therapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Clinical diagnosis transitional cell carcinoma urothelium locally advance metastatic Ineligible cisplatinbased therapy least one follow two medical condition : Calculated creatinine clearance ≤60 mL/min : OR New York Heart Association Classification Stage IIIIV Congestive Heart Failure Measurable disease document image least one unidimensional lesion Adequate performance status ( ECOG 0 , 1 , 2 ) Men woman ≥18 year age Patients radiation surgery indicate Current neuropathy ≥ CTCAE grade 3 Prior radiation ≥ 30 % bone marrow Inadequate renal function : serum creatinine clearance ≤ 20 mL/min Prior allergy vinca alkaloid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Advanced metastatic transitional cell carcinoma urothelium</keyword>
</DOC>